ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$18.85 USD
-0.56 (-2.86%)
Updated Jun 3, 2024 11:12 AM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVBP 18.85 -0.56(-2.86%)
Will AVBP be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AVBP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AVBP
Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
ArriVent BioPharma Welcomes Dr. Hohneker to Board
Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials
AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024